Active substance
Heparin
- SFDA 12
- US FDA 137
- Health Canada 10
- US price lines 6
- NHS prices 2
- WHO EML 1
- Safety 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HEPARINOL 1000 IU/ML INJECTION | 1000 IU/ml | Solution for injection · Intravenous, Subcutaneous | 10 Vial | SAR 165.60 | Generic · Prescription | AIN MEDICARE SDN. BHD. | Valid |
| HEPARINOL 5000 IU/ML INJECTION | 5000 IU/ml | Solution for injection · Intravenous, Subcutaneous | 10 Vial | SAR 317.40 | Generic · Prescription | AIN MEDICARE SDN. BHD. | Valid |
| HEPSAL AMP 10 UNITS-ML | 10 IU/ml | Solution · Intravenous use | 1 Ampoule | SAR 2.70 | Biological · Prescription | WOCKHARDT UK LIMITED | Valid |
| HIKMA HEPARIN 5000 IU/ML | 5000 IU/ml | Solution for injection · Intravenous use | 10 Vial | SAR 317.40 | Biological · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| MONOPARIN 25000 U-ML INJ | 25000 IU/ml | Solution for injection · Intravenous use | 10 Injection Syringe | SAR 6.50 | Biological · Prescription | WOCKHARDT UK LIMITED | Valid |
| MULTIPARIN 1000 UNITS-ML INJ | 1000 IU/ml | Solution for injection/concentrate for solution for infusion · Intravenous use | 10 Vial | SAR 27.85 | Biological · Prescription | WOCKHARDT UK LIMITED | Valid |
| MULTIPARIN 25000 UNITS-ML INJ | 25000 IU/ml | Solution for injection/concentrate for solution for infusion · Intravenous use | 10 Vial | SAR 114.00 | Biological · Prescription | WOCKHARDT UK LIMITED | Valid |
| MULTIPARIN 5000 UNITS-ML INJ | 5000 IU/ml | Solution for injection/concentrate for solution for infusion · Intravenous use | 10 Vial | SAR 63.10 | Biological · Prescription | WOCKHARDT UK LIMITED | Valid |
| Vaxcel Heparin Sodium Injection | 5000 IU/ml | Solution for injection · Intravenous, Subcutaneous | 10 Vial | SAR 213.45 | Generic · Prescription | Kotra pharma M Sdn Bhd | Valid |
| MONOPARIN 1000 U-ML INJ | 1000 IU/ml | Solution for injection · Intravenous use | 1 Ampoule | SAR 1.55 | Biological · Prescription | WOCKHARDT UK LIMITED | Invalid · Not Marketed |
| MONOPARIN 25000 U-ML INJ | 25000 IU/ml | Solution for injection · Intravenous use | 1 Ampoule | SAR 27.85 | Biological · Prescription | WOCKHARDT UK LIMITED | Invalid · Not Marketed |
| MONOPARIN 5000 U-MLINJ | 5000 IU/ml | Solution for injection · Intravenous use | 1 Ampoule | SAR 2.90 | Biological · Prescription | WOCKHARDT UK LIMITED | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ ANTICOAGULATION FOR PATIENTS UNDERGOING CARDIOPULMONARY BYPASS (CBP) & REVERSAL; ANTIPHOSPHOLIPID SYNDROME; BARIATRIC SURGERY; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); DIALYSIS; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; HIP AND KNEE REPLACEMENT SURGERY; HODGKIN'S LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELOFIBROSIS-ADVERSE REACTION MANAGEMENT; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); POLYCYTHEMIA VERA - THROMBOSIS; PORTAL VEIN THROMBOSIS; PULMONARY EMBOLISM; ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI); T-CELL LYMPHOMA-RENAL TOXICITY; VENOUS THROMBOEMBOLISM DISEASE (VTE)-PROPHYLAXIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| HEPARIN SODIUM | 1,000 UNITS/ML; 10,000 UNITS/ML; 20,000 UNITS/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 22 Feb 1972 |
| HEPARIN SODIUM PRESERVATIVE FREE | 1,000 UNITS/ML; 10,000 UNITS/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 22 Feb 1972 |
| HEPARIN SODIUM IN PLASTIC CONTAINER | 1,000 UNITS/ML; 5,000 UNITS/ML; 10,000 UNITS/ML; 20,000 UNITS/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 22 Feb 1972 |
| HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% | 50 UNITS/ML; 100 UNITS/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 22 Feb 1972 |
| HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% | 50 UNITS/ML; 100 UNITS/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 22 Feb 1972 |
| HEPARIN SODIUM | 1,000 UNITS/ML; 5,000 UNITS/ML; 10,000 UNITS/ML; 5,000 UNITS/0.5ML | injectable · injection | HIKMA PHARMS | Prescription | 22 Mar 1972 |
| HEPARIN SODIUM | 5,000 UNITS/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 10 Feb 1978 |
| HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | 200 UNITS/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 28 Apr 1982 |
| HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | 200 UNITS/100ML; 2,000 UNITS/1000ML | injectable · injection | BAXTER HLTHCARE | Prescription | 28 Apr 1982 |
| HEPARIN SODIUM | 5,000 UNITS/ML | injectable · injection | HOSPIRA | Prescription | 28 Apr 1983 |
| HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | 5,000 UNITS/100ML | injectable · injection | HOSPIRA | Prescription | 31 Jan 1984 |
| HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | 5,000 UNITS/100ML; 10,000 UNITS/100ML | injectable · injection | HOSPIRA | Prescription | 31 Jan 1984 |
| HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | 200 UNITS/100ML | injectable · injection | HOSPIRA | Prescription | 31 Jan 1984 |
| HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | 200 UNITS/100ML | injectable · injection | HOSPIRA | Prescription | 31 Jan 1984 |
| HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | 5,000 UNITS/100ML | injectable · injection | HOSPIRA | Prescription | 27 Mar 1985 |
| HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | 10,000 UNITS/100ML; 5,000 UNITS/100ML | injectable · injection | HOSPIRA | Prescription | 27 Mar 1985 |
| HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | 10,000 UNITS/100ML | injectable · injection | HOSPIRA | Prescription | 27 Mar 1985 |
| HEPARIN SODIUM PRESERVATIVE FREE | 10,000 UNITS/ML | injectable · injection | HOSPIRA | Prescription | 4 May 1987 |
| HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | 4,000 UNITS/100ML | injectable · injection | B BRAUN | Prescription | 20 Jul 1992 |
| HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | 5,000 UNITS/100ML; 10,000 UNITS/100ML | injectable · injection | B BRAUN | Prescription | 20 Jul 1992 |
| HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | 200 UNITS/100ML | injectable · injection | B BRAUN | Prescription | 20 Jul 1992 |
| HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | 200 UNITS/100ML | injectable · injection | B BRAUN | Prescription | 20 Jul 1992 |
| HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | 5,000 UNITS/100ML; 10,000 UNITS/100ML | injectable · injection | B BRAUN | Prescription | 20 Jul 1992 |
| HEPARIN SODIUM | 1,000 UNITS/ML; 5,000 UNITS/ML; 10,000 UNITS/ML | injectable · injection | HOSPIRA INC | Prescription | 31 Aug 2009 |
| HEPARIN SODIUM | 1,000 UNITS/ML; 5,000 UNITS/ML; 10,000 UNITS/ML | injectable · injection | SAGENT PHARMS | Prescription | 30 Jun 2010 |
112 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| HEPARIN LEO 100UNIT/ML | 00727520 | 100 UNIT / ML | SOLUTION · EXTRACORPOREAL | LEO PHARMA INC |
| HEPARIN LEO INJ 1000UNIT/ML | 00453811 | 1000 UNIT / ML | SOLUTION · INTRAVENOUS; SUBCUTANEOUS | LEO PHARMA INC |
| HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION | 01990748 | 2 UNIT / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
| HEPARIN SODIUM INJECTION USP | 02382326 | 10000 UNIT / ML | SOLUTION · SUBCUTANEOUS; INTRAVENOUS | PFIZER CANADA ULC |
| HEPARIN SODIUM INJECTION USP | 02456958 | 5000 UNIT / 0.5 ML | SOLUTION · SUBCUTANEOUS | STERINOVA INC. |
| HEPARIN SODIUM INJECTION USP | 02548488 | 5000 UNIT / 0.5 ML | SOLUTION · INTRAVENOUS; SUBCUTANEOUS | STERIMAX INC |
| HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE) | 02303086 | 1000 UNIT / ML | SOLUTION · INTRAVENOUS; SUBCUTANEOUS | SANDOZ CANADA INCORPORATED |
| HEPARIN SODIUM INJECTION, USP | 02264307 | 10000 UNIT / ML | SOLUTION · INTRAVENOUS; SUBCUTANEOUS | FRESENIUS KABI CANADA LTD |
| HEPARIN SODIUM INJECTION, USP | 02264315 | 1000 UNIT / ML | SOLUTION · INTRAVENOUS; SUBCUTANEOUS | FRESENIUS KABI CANADA LTD |
| HEPARIN SODIUM INJECTION, USP | 02392453 | 10000 UNIT / ML | SOLUTION · INTRAVENOUS; SUBCUTANEOUS | FRESENIUS KABI CANADA LTD |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | HEPARIN SOD 10,000 UNIT/ML VL | $2.09398 | per ML | 23 Sep 2026 |
| US NADAC | HEPARIN SOD 5,000 UNIT/ML SYRG | $3.19142 | per ML | 23 Sep 2026 |
| US NADAC | HEPARIN SOD 5,000 UNIT/ML VIAL | $1.1796 | per ML | 23 Sep 2026 |
| US NADAC | HEPARIN SODIUM 10,000 UNIT/ML VIAL | $2.09398 | per ML | 23 Sep 2026 |
| US NADAC | HEPARIN SODIUM 5,000 UNIT/0.5 ML SYRINGE | $5.8995 | per ML | 20 May 2026 |
| US NADAC | HEPARIN SODIUM 5,000 UNIT/ML VIAL | $1.1796 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Heparin sodium 200units/2ml patency solution ampoules | £21.17 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Heparin sodium 50units/5ml patency solution ampoules | £20.20 | 10 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 10.2. Medicines affecting coagulation · core (EML); complementary (EMLc)
Acute ischaemic heart disease; Unstable angina; Venous thromboembolism
Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial (EML); 5000 IU per mL in 1 mL ampoule or vial
Safety signals and safety-related labeling changes
- US FDA 24 Sep 2025 HEPARIN SODIUM PRESERVATIVE FREE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 24 Oct 2024 HEPARIN SODIUM — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Oct 2024 HEPARIN SODIUM IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Oct 2024 HEPARIN LOCK FLUSH — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 24 Oct 2024 HEPARIN LOCK FLUSH — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 24 Oct 2024 HEPARIN SODIUM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 24 Oct 2024 LIQUAEMIN LOCK FLUSH — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 24 Oct 2024 LIQUAEMIN SODIUM — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 24 Oct 2024 LIQUAEMIN SODIUM PRESERVATIVE FREE — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Combinations containing Heparin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.